Type 2 Diabetes Uncontrolled on GLP-1 RA or Dual GIP/GLP-1 RA: What to Do Next
When a GLP-1 receptor agonist or dual GIP and GLP-1 receptor agonist has been optimally titrated yet the individualized glycemic goal remains out of reach, a defined next-line approach is indicated for type 2 diabetes.
A GLP-1 RA or dual GIP and GLP-1 RA was initiated and titrated to the appropriate maintenance dose, but the individualized glycemic goal — A1C below 7% — was not achieved or sustained. Failure to reach that target is the trigger for escalation to the next step.
When greater glucose-lowering potency is needed, basal insulin — either human NPH or a long-acting insulin analog — is the indicated next injectable agent. The specific choice between agents, the starting approach, and the individualized titration strategy are detailed in the full protocol.
Fasting plasma glucose reaches its individualized target without causing hypoglycemia.
References
DOI: 10.2337/dc26-S009
- When even greater potency of glucose reduction is needed, basal insulin, either human NPH or a long-acting insulin analog, should be initiated.
- Increase 2 units every 3 days to reach fasting plasma glucose goal without hypoglycemia.